










## Neurology

 <p><b>Pepinemab</b> Support from Alzheimer's Association &amp; Alzheimer's Drug Discovery Foundation</p>		<p>Data 2H 2024</p>
		<p>Published, Nature Medicine</p>






## Oncology

<p><b>Pepinemab + Pembrolizumab</b> KEYNOTE-B84 Partnered with <b>Merck Sharp &amp; Dohme</b></p>		<p>Interim analysis reported 4Q 2023</p>
<p><b>Pepinemab + Avelumab</b> NCT03690986 <b>Merck, KGaA Darmstadt</b>, University of Rochester, Gateway Discovery Fdn.</p>		<p>Enrolling</p>
<p><b>Pepinemab + Avelumab</b> CLASSICAL-Lung Partnered with Merck, KGaA Darmstadt</p>		<p>Complete Published</p>


## Investigator-sponsored trials

<p><b>Pepinemab + Nivolumab and/or Ipilimumab</b> NCT03769155 Emory University with <b>Bristol Myers Squibb</b></p>		<p>Enrollment Complete</p>
<p><b>Pepinemab + Trastuzumab + DC Vaccine</b> NCT05378464 H. Lee Moffitt Cancer Center</p>		<p>Enrolling</p>

## Drug Discovery ActivMab Technology

<p><b>VX18</b></p>		
<p><b>CXCR5 Mab</b> Available for licensing</p>		
<p><b>CXCL13 Mab</b> Available for licensing</p>		
<p><b>CCR8 Mab</b> Available for licensing</p>		
<p><b>Claudin18.2 Mab</b> Available for licensing</p>		

**ActivMab®** Maximizing success to find Ab therapeutics for difficult-to-drug targets

Antibody Drug Discovery  
Antigen Virus Particles 



**CUSTOM PROJECTS**  
Multiple pharma and biotech

CONTACT US for custom projects!  
View our catalog on Science Exchange